We are a leading gene editing company pioneering breakthroughs with our proprietary hypercompact CRISPR Cas platform technology to redefine the boundaries of what's possible.

Our platform provides a comprehensive suite of editing solutions - including K/I, K/O, and base editing - all delivered within a single AAV vector.

With enhanced target specificity and improved efficiency protected by our own patents, we are setting a new standard for in-vivo gene editing therapies and ex-vivo applications, opening new frontiers in the treatment of genetic diseases.